Lytics in stroke

[This was somewhat up to date in 2011 when it was first written but it is decidedly out of date at this point. The train has not only left the station for tPA but has indeed morphed into some kind of time travelling, flying train from Back to the Future at this point. I remain sceptical (like many in EM) about the evidence base for tPA in stroke but I keep this here as a useful reminder of how important it is to read the literature in detail]

This has been an interest of mine for a while. So much so that I’ve gone and written a slightly meandering epic on it all…

All the hospitals I have worked in recently have well set-up and well ran acute stroke services which involve lysis. Despite my scepticism on the evidence base for lytics in stroke, medicine and emergency medicine in particular is a team sport so just because I find myself in the position of scepticism does not allow me to deny patients access to other professionals and treatments that I may differ from. Just remember you work for  a hospital – don’t get fired over it. If your hospital does tPA for stroke and you’re involved then you’d be best to do it as well as you possibly can.

I’ve endeavoured to keep this somewhat up to date but the sheer volume of published literature makes it difficult.

I’ve also collated a table of some of the numbers from the studies regarding outcomes and adverse events. I’ve tried to use the NINDS definition for SICH if I can find it in the corresponding paper. Let me know if I’ve got any of the numbers wrong.

I’ve added my thoughts on IST-3 at the very bottom and updated the table below.

Note:

  • I can’t find MRS data for the atlantis A trial
  • only the most recent ECASS data reported a NINDS definition of SICH
  • the SITS studies are both observational registry data
  • This was compiled from data in 2011. Obviously there’s lots more stroke data than this
Part One
Part Two
Part Three
Part Four
Part Four and a half
Part Five
IST 3

 

References:

The RCTs

  • Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurology 2009 Feb.;8(2):141–150. PMCID 2730486
  • Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurology 2008 Apr.;7(4):299–309.PMID 18296121
  • Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial–Italy (MAST-I) Group. The Lancet 1995 Dec.;346(8989):1509 -1514. PMID: 7491044 
  • Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial–Europe Study Group (MAST-E). N Engl J Med 1996 Jul.;335(3):145–150. PMID: 8657211
  • Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996 Sep.;276(12):961–966. PMID: 8805730
  • Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS (B) Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999 Dec.;282(21):2019–2026. PMID: 10591384 
  • The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.(ATLANTIS A) Stroke 2000 Apr.;31(4):811–816.  PMID 10753980
  • Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (NINDS). N Engl J Med 1995 Dec.;333(24):1581–1587. PMID: 7477192
  • Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995 Oct.;274(13):1017–1025.1. PMID: 7563451 
  • Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. The Lancet 1998 Oct.;352(9136):1245–1251. PMID: 9788453 
  • Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke (ECASS III). N Engl J Med 2008 Sep.;359(13):1317–1329. PMID: 18815396 
  • The IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012 May 23. PMID: 22632908

Some of the #FOAMed resources on lytic for stroke debate:

LITFL – CCC Stroke Thrombolysis

LITFL – Michelle Johnston on tPA for stroke

TheNNT.com

EMCrit Cage Match – Jagoda v Swaminathan

The SGEM

Busting the Clotbusters – Domhnall Brannigan

SMART EM – thrombolytics for stroke

Oregon Stoke Network debate: Jerry Hoffman and Greg Albers [2hr video]

19 Replies to “Lytics in stroke

  1. Hey Andy, was just re-reading your awesome summary on lysis and nipped over to the IST3 website and noticed one small detail which interested (concerned?) me. I had a look at the recruitment and randomisation process, and although at face value it seems useful that current off-label “indications” would be included, I wondered somewhat how they would analyse the data from those they state as having a “clear indication” for tPA. The value of the trial could hinge on how they incorporate the data from this group… Just a thought, care to comment? Will DM you a screen grab on the bit I mean on Twitter if I can.

    • Good spot Domhnall, I didn’t read their methods in that much detail. I thought they were doing a full double blind RCT of all comer stroke pts but they’re clearly not

      I feel a new post coming on…

  2. Pingback: Some updates on IST-3 | Emergency Medicine Ireland

  3. Pingback: On IST-3 and why we still don’t have the answer we were looking for… |

  4. Pingback: What am I missing here? « DrGDH

  5. Pingback: IST-3 and thrombolysis in Stroke

  6. Pingback: Neurology Resources for Medical Students (1/2) - Manu et Corde

  7. Pingback: On IST-3 and why we still don't have the answer we were looking for... - Emergency Medicine Ireland

  8. Pingback: Some updates on IST-3 - Emergency Medicine Ireland

  9. Pingback: Thrombolysis for stroke head to head in the BMJ - Emergency Medicine Ireland

  10. Pingback: The LITFL Review 027 - Life in the FastLane Medical Blog

  11. Pingback: IST-3 and thrombolysis in Stroke

  12. Pingback: JC: Time is brain...., calling #FOAMagitators. St.Emlyn's - St Emlyns

  13. Pingback: Vem ska man tro på? Om trombolys vid stroke. | akut eftertanke

  14. Pingback: The Use of Thrombolysis as a Treatment for Acute Stroke

  15. Pingback: Sweets » Blog Archive Trombolys vid stroke - finns det skäl att vara skeptisk? » Sweets

  16. Pingback: Stroke Thrombolysis • LITFL

  17. Pingback: IST-3 and thrombolysis in Stroke • LITFL • Schrödinger’s Fence

  18. Pingback: The Use of Thrombolysis as a Treatment for Acute Stroke • LITFL

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.